Skip to content
CancerIndex

Loading the knowledge graph…

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study — knowledge graph · CancerIndex